ME02842B - Potpuno ljudska antitijela specifična za cadm1 - Google Patents

Potpuno ljudska antitijela specifična za cadm1

Info

Publication number
ME02842B
ME02842B MEP-2017-194A MEP19417A ME02842B ME 02842 B ME02842 B ME 02842B ME P19417 A MEP19417 A ME P19417A ME 02842 B ME02842 B ME 02842B
Authority
ME
Montenegro
Prior art keywords
antibody
variable region
chain variable
seq
cadm1
Prior art date
Application number
MEP-2017-194A
Other languages
German (de)
English (en)
French (fr)
Inventor
Jonathan Alexander Terrett
Heidi Leblanc
Haichun Huang
Erika Meaddough
Chin Pan
Bingliang Chen
Chetana Rao-Naik
Original Assignee
Squibb & Sons Llc
Oxford Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Llc, Oxford Biotherapeutics Ltd filed Critical Squibb & Sons Llc
Publication of ME02842B publication Critical patent/ME02842B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (14)

1. Izolovana monoklonalna antitijela, ili njegov deo koji vezuje antigen, ili fragment antitela koji vezuje epitop na ljudski CADM1 i obuhvata promenljivi region teškog lanca koji obuhvata sekvencu amino kiseline iznetu u SEK ID BR: 19, 20, ili 21 promenljivi region lakog lanca koji obuhvata sekvencu amino kiseline iznetu u SEK ID BR: 22, 23, ili 24.
2. Izolovana monoklonalna antitelo, ili njego deo koji vezuje antigen, ili fragment antitela koji vezuje epitop na ljudski CADM1 i koji obuhvata:(a) promenljivi region teškog lanca CDR1 koji obuhvata SEK ID BR: 1, promenljivi region teškog lanca CDR2 koji obuhvata SEK ID BR: 4, promenljivi region teškog lanca CDR3 koji obuhvata SEK ID BR: 7, promenljivi region lakog lanca CDR1 koji obuhvata SEK ID BR: 10, promenljivi region lakog lanca CDR2 koji obuhvata SEK ID BR: 13, i promenljivi region lakog lanca CDR3 koji obuhvata SEK ID BR: 16;ili(b) promenljivi region teškog lanca CDR1 koji obuhvata SEK ID BR: 2, promenljivi region teškog lanca CDR2 koji obuhvata SEK ID BR: 5, promenljivi region teškog lanca CDR3 koji obuhvata SEK ID BR: 8, promenljivi region lakog lanca CDR1 koji obuhvata SEK ID BR: 11, promenljivi region lakog lanca CDR2 koji obuhvata SEK ID BR: 14, i promenljivi region lakog lanca CDR3 koji obuhvata SEK ID BR: 17;ili(e) promenljivi region teškog lanca CDR1 koji obuhvata SEK ID BR: 3,promenljivi region teškog lanca CDR2 koji obuhvata SEK ID BR: 6, promenljivi region teškog lanca CDR3 koji obuhvata SEK ID BR: 9, promenljivi region lakog lanca CDR1 koji obuhvata SEK ID BR: 12, promenljivi region lakog lanca CDR2 koji obuhvata SEK ID BR: 15, i promenljivi region lakog lanca CDR3 kojiobuhvata SEK IDBR: 18.
3. Antitelo iz patentnog zahteva 1 ili patentnog zahteva 2:(A) pri čemu pomenuto antitelo jeste antitelo pune dužine lgG1, lgG2, lgG3, ili lgG4 izotipa;(B) pri čemu se pomenuto antitelo bira iz grupe koja obuhvata celo antitelo, fragment antitela, humanizovano antitelo, ljudsko antitelo, antitelo jednog lanca, projektovano antitelo koje kao rezultat daje povećano vezivanje na Fc receptore i/ili povećanu učinkovitost za ADCC, i bispecifično antitelo; (C) pri čemu ovo antitelo koje se konjuguje na terapijski agens, poželjno gde je terapijski agens je citotoksin ili radioaktivni izotop; ili(D) pri čemu se pomenuto antitelo vezuje na ljudski CADM1 sa EC50 u opsegu od < 50 nM, preporučljivo pri ćemu se pomenuto antitelo vezuje na ljudski CADM1 sa ECso u opsegu < 10 nM, i još preporućljivije pri ćemu se pomenuto antitelo vezuje na ljudski CADM1 sa ECso u opsegu< 1 nM.
4. Supstanca koja obuhvata izolovana antitelo, deo koji vezuje antigen ili fragment antitela koji vezuje epitop na ljudski CADM1 iz patentnog zahteva 1 ili patentnog zahteva 2 i farmaceutski prihvatljivog nosača.
5. Izolovani moleku! nukleinske kiseline koji kodira teški ili laki lanac antitela ili deo koji vezuje antigen ili fragment antitela koji vezuje epitop na ljudski CADM1 iz patentnog zahteva 1 ili patentnog zahteva 2; ili vektor ekspresije koji obuhvata pomenuti moleku! nukleinske kiseline; ili ćeliju domaćina koja obuhvata pomenuti vektor ekspresije.
6. Postupak za pripremu anti-CADM1 antitela, pomenuti postupak obuhvata korake:dobijanja ćelije domaćina koja obuhvata jedan ili više molekula nukleinske kiseline koji kodira antitelo iz patentnog zahteva 1 ili patentnog zahteva 2, rast ili uzgoj ćelije domaćina u kulturi ćelije domaćina; obezbeđivanje uslova kulture ćeije domaćina pri čemu se ispoljava jedan ili više molekula nukleinske kiseline; i oporavlja antitelo iz ćelije domaćina ili iz kulture ćelije domaćina.
7 Izolovana monoklonalna antitelo, ili njegov deo koji vezuje antigen, ili fragment antitela kako je definisano u patentnom zahtevu 1 ili patentnom zahtevu 2 za upotrebu u postupku za lečenje ili sprečavanje bolesti povezane sa ciljnim ćelijama koje ispoljavaju CADM1, preporučljivo pri čemu je pomenuta bolest kancer kod čoveka, i još preporućljivije pri čemu se pomenuti kancer kod čoveka bira iz grupe koja obuhvata: sitnoćelijski kancer pluća, leukemija T ćelije kod odraslih, nesitnoćelijski kancer pluća (uključujući skvamozne karcinome i adenokarcinome), melanom, kancer dojke, kolorektalni kancer, kancer jajnika, kancer prostate, neuroendokrine kancere ukljućujući kancere pluća, nadbubrežne žlezde, hipofize, Gl trakta, bubrega, jetre (ukljućujući hepatoćelijske karcinome), pankreas (uključujući insulinome i glukagonome), glioblastome, i kardinoidne tumore uključujući tumore pankreasa, pluća, Gl trakta, jetre i bubrega.
8. Izolovana monoklonalna antitelo ili njegov deo koji vezuje antigen, ili fragment antitela prema patentnom zahtevu 1 ili patentnom zahtevu 2 koji vezuje epitop na ljudski CADM1 i obuhvata promenljivi region teškog lanca i promenljivi region lakog lanca izabrane iz grupe koja obuhvata:amino kiselinu promenljivog regiona teškog lanca iznetu u SEK ID BR: 19 i sekvencu amino kiseline promenljivog regiona teškog lanca iznetu u SEK ID BR: 22;sekvencu amino kiseline promenljivog regiona teškog lanca iznetu u SEK ID BR: 20 i sekvencu amino kiseline promenljivog regiona lakog lanca iznetu u SEK ID BR: 23; isekvencu amino kiseline promenljivog regiona teškog lanca iznetu u SEK ID BR: 21 i sekvencu amino kiseline promenljivog regiona lakog lanca iznetu u SEK ID BR: 24.
9. Izolovane antitelo iz patentnog zahteva 8:pri čemu se pomenuto antitelo bira iz grupe koja obuhvata: celo antitelo, fragment antitela, humanizovano antitelo, ljudsko antitelo, antitelo jednog lanca, projektovano antitelo koje kao rezultat daje povećano vezivanje na Fc receptore i/ili povećanu učinkovitost za ADCC, i bispecifično antitelo;
10. Supstanca koja obuhvata izolovane antitelo ili njegov deo koji vezuje antigen iz patentnog zahteva 8 i farmaceutski prihvatljiv nosač.
11 . Izolovani molekul nukleinske kiseline koji kodira teški ili laki lanac izolovanog antitela ili njegov deo koji vezuje antigen iz patentnog zahteva 8; ili vektor ekspresije koji obuhvata pomenuti molekul nukleinske kiseline; ili ćeliju domaćina koja obuhvata pomenuti vektor ekspresije.
12. Hibridom koji ispoljava antitelo ili deo koji vezuje antigen ili fragment antitela koji vezuje epitop na ljudski CADM1 iz bilo kog od patentnih zahteva 1, 2 ili 8.
13. Postupak za pravljenje antitela iz bilo kog od patentnih zahteva 1, 2 ili 8 koji obuhvata korake:imunizovanja transgenske životinje koje obuhvata ljudske gene imunoglobulina sa CADM1 peptidom;oporavljanja B ćelje iz pomenute transgenske životinje;pravljenje hibridoma iz pomenutih B ćelija;selekcija hibridoma koji ispoljavaju antitela koja vezuju CADM1; ioporavljanja pomenutih antitela koja vezuju CADM1 iz pomenutih izabranih hibridoma.
14. Postupak za pravljenje anti-CADM1 antitela, pomenuti postupak obuhvata korake:imunizovanja transgenske životinje koja obuhvata ljudske gene imunoglobulina sa CADM1 peptidom;oporavljanja mRNK iz B ćelije pomenute transgenske životinje;pretvaranje pomenute mRNK u cDNK;ispoljavanje pomenute cONK u fagima tako da se anti-CADM1 antitela kodirana pomenutom cDNKpredstavljaju na površini pomenutih faga;biranje faga koji predstavljaju anti-CADM1 antitela;oporavljanja molekula nukleinske kiseline iz pomenutih izabranih faga koji kodiraju pomenute anti CADM1 imunoglobulina;ispoljavanje pomenutih oporavljenih molekula nukleinske kiseline u ćeliji domaćinu; ioporavljanje antitela kako je definisano u bilo kom od patentnih zahteva 1, 2 ili 8 iz pomenute ćelije domaćina koji vežu CADM1.
5. lmunokonjugat koji obuhvata (i) izolovane antitelo kako se tvrdi u patentnom zahtevu 8 ili patentnom zahtevu 9 i (ii) terapijski agens.
MEP-2017-194A 2009-03-05 2010-03-05 Potpuno ljudska antitijela specifična za cadm1 ME02842B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20947109P 2009-03-05 2009-03-05
US20939009P 2009-03-05 2009-03-05
EP10708470.9A EP2403878B1 (en) 2009-03-05 2010-03-05 Fully human antibodies specific to cadm1
PCT/US2010/026315 WO2010102175A1 (en) 2009-03-05 2010-03-05 Fully human antibodies specific to cadm1

Publications (1)

Publication Number Publication Date
ME02842B true ME02842B (me) 2018-01-20

Family

ID=42144944

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-194A ME02842B (me) 2009-03-05 2010-03-05 Potpuno ljudska antitijela specifična za cadm1

Country Status (25)

Country Link
US (2) US8420084B2 (me)
EP (1) EP2403878B1 (me)
JP (1) JP5816558B2 (me)
KR (1) KR101769160B1 (me)
CN (1) CN102341412B (me)
AU (1) AU2010221186B2 (me)
BR (1) BRPI1009232B1 (me)
CA (1) CA2753702C (me)
CY (1) CY1119539T1 (me)
DK (1) DK2403878T3 (me)
EA (1) EA028336B1 (me)
ES (1) ES2639026T3 (me)
HR (1) HRP20171274T1 (me)
HU (1) HUE034196T2 (me)
IL (1) IL214779A (me)
LT (1) LT2403878T (me)
ME (1) ME02842B (me)
MX (1) MX2011009220A (me)
NZ (1) NZ594682A (me)
PL (1) PL2403878T3 (me)
PT (1) PT2403878T (me)
SG (1) SG173742A1 (me)
UA (1) UA102891C2 (me)
WO (1) WO2010102175A1 (me)
ZA (1) ZA201105918B (me)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK2069793T3 (en) * 2006-08-29 2017-04-24 Oxford Biotherapeutics Ltd IDENTIFICATION OF PROTEIN IN CONNECTION WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER
ME02842B (me) 2009-03-05 2018-01-20 Squibb & Sons Llc Potpuno ljudska antitijela specifična za cadm1
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
JP6440968B2 (ja) * 2013-05-28 2018-12-19 国立大学法人 宮崎大学 ＩｇＳＦ４／ＴＳＬＣ１／ＣＡＤＭ１を特異的に認識できる抗体
CN107406504B (zh) * 2015-11-19 2021-04-30 蔡则玲 Ctla-4抗体及其用途
JP7229503B2 (ja) 2018-03-16 2023-02-28 国立大学法人 東京大学 ＣＡＤＭ１ｖ９認識抗体
JP7401538B2 (ja) * 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ｃｌｄｎ１８．２抗体およびその使用
CN115477698B (zh) * 2020-08-19 2024-10-25 重庆医科大学 一种rbd特异性单克隆抗体和应用
WO2022239766A1 (ja) * 2021-05-11 2022-11-17 国立大学法人 東京大学 抗ｃａｄｍ１抗体
TW202321296A (zh) * 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
KR20230062691A (ko) 2021-10-29 2023-05-09 주식회사 이뮤노로지컬디자이닝랩 Cadm1에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
KR20230061710A (ko) 2021-10-29 2023-05-09 주식회사 이뮤노로지컬디자이닝랩 Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
US20250236642A1 (en) * 2022-02-25 2025-07-24 Nec Corporation Pharmaceutical composition for treatment or prevention of adult t-cell leukemia
JP7270944B1 (ja) * 2022-09-13 2023-05-11 学校法人近畿大学 抗ｃａｄｍ１抗体またはその抗原結合断片
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5712375A (en) 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5763566A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DK0616640T3 (da) 1991-12-02 2004-12-20 Medical Res Council Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6114120A (en) 1995-05-03 2000-09-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
AU727608B2 (en) 1995-10-03 2000-12-14 Scripps Research Institute, The CBI analogs of CC-1065 and the duocarmycins
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
DE69825048D1 (de) 1997-05-22 2004-08-19 Scripps Research Inst Analoga von duocarmycin and cc-1065
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
NZ504548A (en) 1997-12-03 2003-06-30 Genentech Inc Polypeptides and nucleic acids encoding human chordin
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
WO1999057132A1 (en) 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DE69942861D1 (de) 1998-08-07 2010-11-25 Immunex Corp Ldcam genannte moleküle
WO2000008057A2 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
CA2348824A1 (en) 1998-10-28 2000-05-25 Human Genome Sciences, Inc. 12 human secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
AU1618500A (en) 1998-11-12 2000-05-29 Incyte Pharmaceuticals, Inc. Human cell surface receptor proteins
MXPA01005425A (es) 1998-12-01 2002-04-24 Genentech Inc Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK1609863T3 (da) 1999-03-23 2008-12-15 Genentech Inc Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002014577A1 (fr) * 2000-08-04 2002-02-21 Japan Lifeline Co., Ltd Procede pour produire un element metallique cylindrique a paroi mince
AU2001286514A1 (en) 2000-08-15 2002-02-25 National Cancer Center Research Institute Diagnosis and treatment of tumor-suppressor associated disorders
CA2421122A1 (en) 2000-09-01 2002-03-07 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US20020157122A1 (en) * 2000-10-27 2002-10-24 Wong Philip C. Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
WO2002066643A2 (en) 2000-11-13 2002-08-29 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
EP1404356B1 (en) 2001-06-11 2011-04-06 Medarex, Inc. Method for designing cd10-activated prodrug compounds
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
JP2005502703A (ja) 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1464709B1 (en) * 2003-03-31 2007-12-26 Stichting Researchfonds Pathologie Detection of HPV-induced invasive cancers and their precursor lesions with invasive potential
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP2261244A3 (en) 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
EP1648935A2 (en) 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
JP4227881B2 (ja) 2003-11-13 2009-02-18 財団法人宮崎県産業支援財団 成人ｔ細胞白血病診断薬
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1817335A2 (en) 2004-10-29 2007-08-15 Genentech, Inc. Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006090750A1 (ja) * 2005-02-28 2006-08-31 Institute For Antibodies Co., Ltd. 抗IgSF4抗体及びその利用
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
JP4536588B2 (ja) 2005-05-11 2010-09-01 財団法人宮崎県産業支援財団 成人ｔ細胞白血病の診断器具
US7842467B1 (en) 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
JP5131946B2 (ja) 2005-09-13 2013-01-30 国立大学法人 東京大学 がんの診断、処置および／または予防、および／または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法
EP1940470B1 (en) 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
EA015324B1 (ru) 2005-10-26 2011-06-30 Медарекс, Инк. Способы и соединения для получения аналогов сс-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007074832A1 (ja) 2005-12-28 2007-07-05 Japan Health Sciences Foundation 小細胞肺がんの診断のための方法、システムおよび組成物ならびに関連するスクリーニング方法
US7842291B1 (en) 2006-05-22 2010-11-30 Celera Corporation Methods and compositions for diagnosing and treating diseases
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
DK2069793T3 (en) * 2006-08-29 2017-04-24 Oxford Biotherapeutics Ltd IDENTIFICATION OF PROTEIN IN CONNECTION WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER
EP2092074A4 (en) 2006-11-02 2010-06-09 Univ Yale EVALUATION OF THE EFFECTIVENESS OF EGGS
EP1918299A1 (en) 2006-11-03 2008-05-07 Universite De Geneve Modulators of cell adhesion molecules and use thereof
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CA2682916A1 (en) 2007-04-06 2008-11-27 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of cervical cancer
WO2008142693A2 (en) 2007-05-22 2008-11-27 Yeda Research And Development Co. Ltd. Regulation of myelination by nectin-like (necl) molecules
AU2008284271B2 (en) * 2007-08-07 2014-03-13 E. R. Squibb & Sons, L.L.C. Matriptase protein and uses thereof
US20100247430A1 (en) 2007-08-30 2010-09-30 Andrew Chan Methods and Compositions for Modulating T Cells
US8426140B2 (en) 2007-09-28 2013-04-23 Royal College Of Surgeons In Ireland Method of assessing colorectal cancer status in an individual
EP2128259A1 (en) 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging
AU2010208394A1 (en) 2009-01-27 2011-09-08 Hologic, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
ME02842B (me) * 2009-03-05 2018-01-20 Squibb & Sons Llc Potpuno ljudska antitijela specifična za cadm1

Also Published As

Publication number Publication date
HRP20171274T1 (hr) 2017-10-20
DK2403878T3 (en) 2017-09-18
WO2010102175A1 (en) 2010-09-10
IL214779A (en) 2015-11-30
AU2010221186A1 (en) 2011-09-08
LT2403878T (lt) 2017-10-10
US8420084B2 (en) 2013-04-16
JP5816558B2 (ja) 2015-11-18
EA201101242A1 (ru) 2012-04-30
MX2011009220A (es) 2011-09-28
NZ594682A (en) 2013-06-28
BRPI1009232A2 (pt) 2021-01-26
HUE034196T2 (en) 2018-02-28
EA028336B1 (ru) 2017-11-30
CY1119539T1 (el) 2018-03-07
CN102341412A (zh) 2012-02-01
ES2639026T3 (es) 2017-10-25
PL2403878T3 (pl) 2017-12-29
AU2010221186B2 (en) 2013-08-22
PT2403878T (pt) 2017-09-01
US20120093826A1 (en) 2012-04-19
KR101769160B1 (ko) 2017-08-17
JP2012519492A (ja) 2012-08-30
US20130156788A1 (en) 2013-06-20
KR20110126739A (ko) 2011-11-23
CA2753702A1 (en) 2010-09-10
BRPI1009232B1 (pt) 2022-05-03
EP2403878A1 (en) 2012-01-11
EP2403878B1 (en) 2017-06-14
ZA201105918B (en) 2012-10-31
SG173742A1 (en) 2011-09-29
UA102891C2 (uk) 2013-08-27
CA2753702C (en) 2017-01-03
CN102341412B (zh) 2018-01-05
IL214779A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
ME02842B (me) Potpuno ljudska antitijela specifična za cadm1
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2012523848A5 (me)
JP2005507635A5 (me)
JP2012519492A5 (me)
RU2009107494A (ru) АНТИТЕЛА К ErbB2
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2020503870A5 (me)
JP2020510422A5 (me)
JP2017114866A5 (me)
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2010533498A5 (me)
JP2010246565A5 (me)
JP2013523166A5 (me)
JP2009297037A5 (me)
RU2019111277A (ru) Новые моноклональные антитела к белку программируемой смерти 1(pd-1)
WO2022166940A1 (en) Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
JP2007526880A5 (me)
WO2022135536A1 (zh) Cd3人源化抗体及其应用
JP2013535191A5 (me)
JPWO2019224717A5 (me)
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
JP2013520984A5 (me)
RU2019143101A (ru) Новое анти-с-мет антитело и его применение